The Amyotrophic Lateral Sclerosis Therapeutics Market: A Growing Frontier in Neurodegenerative Care
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that gradually weakens muscles and impairs physical function, leaving patients and their families in urgent need of effective treatment options. As awareness of the disease grows worldwide and pharmaceutical innovation accelerates, the Amyotrophic Lateral Sclerosis Therapeutics Market has emerged as a critical and fast-evolving segment within the broader pharmaceutical industry. The global amyotrophic lateral sclerosis therapeutics market was valued at USD 0.89 billion in 2025, and it is projected to grow from USD 1.03 billion in 2026 to USD 2.19 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 9.93% during the forecast period, according to Fortune Business Insight.
Understanding the Disease and Its Treatment Landscape
ALS is a disorder that attacks nerve cells controlling voluntary muscle movement, leading to progressive weakness and, eventually, loss of mobility, speech, and breathing capability. While there is currently no cure for the disease, medications, assistive devices, and physical and speech therapies help manage symptoms and slow disease progression. The drugs approved for treating ALS include tofersen, edaravone, and riluzole, each of which plays a role in alleviating symptoms and, in some cases, moderating the pace of neurological decline, according to Fortune Business Insight.
Key Drivers Fueling Market Growth
The rising prevalence of Lou Gehrig's disease is one of the strongest forces propelling the market forward. Citing a study published by John Wiley & Sons in 2021, global ALS cases are expected to increase from 222,000 in 2015 to 376,000 by 2040, according to Fortune Business Insight. This growing disease burden is placing pressure on healthcare systems and pharmaceutical companies alike to accelerate the development and distribution of effective therapies.
Advocacy and awareness organizations have also played a meaningful role in shaping market dynamics. Groups such as Asha Ek Hope, the ALS Association, I AM ALS, Asociación Colombiana de Esclerosis Lateral Amiotrófica (ACELA), Asociación ELA Argentina, and ALS Netherlands have intensified efforts to raise public understanding of the disease, which in turn has increased demand for effective treatment options, according to Fortune Business Insight.
Government initiatives are another significant growth catalyst. For instance, the Canadian government invested approximately USD 40.0 million in ALS research through the Canadian Institutes of Health Research (CIHR) in June 2023, according to Fortune Business Insight. Such public investment underscores a broader global commitment to combating the disease and supporting therapeutic innovation.
Pharmaceutical companies are also intensifying efforts to bring novel drug candidates to market. AL-S Pharma initiated Phase 2 clinical trials for its drug candidate AP-101 in September 2021, while Clene Nanomedicine began Phase 2 trials for CNMAu8 in December 2021, according to Fortune Business Insight. These pipeline developments reflect a broader trend of innovation aimed at expanding treatment options beyond the currently approved therapies.
Restraining Factors
Despite the promising growth trajectory, the market faces notable headwinds. High treatment costs remain a significant barrier to adoption. Radicava ORS, a Mitsubishi Tanabe Pharma product, can cost around USD 171,000.0 per year, according to Fortune Business Insight. Additionally, ALS therapeutics are associated with side effects such as dizziness, weakness, breathing problems, bladder pain, and blurred vision, which often lead patients to explore alternative treatment approaches like nutritional support, physical therapy, and surgical interventions, according to Fortune Business Insight.
Market Segmentation Insights
The market is segmented by drug type into tofersen, edaravone, riluzole, and others. The "others" segment held the largest share in 2023, driven largely by strong sales of Relyvrio, an AMYLYX Pharmaceuticals product, though the drug was later withdrawn in April 2024 following failure in late-stage clinical trials, according to Fortune Business Insight. Looking ahead, edaravone is expected to dominate the market during the forecast period, holding a 57.88% share in 2026, owing to its approval across major markets including the U.S., Brazil, Canada, Switzerland, China, and Thailand, according to Fortune Business Insight.
By route of administration, the oral segment led the market with a 50.24% share in 2026, supported by strong sales of oral drugs such as Radicava, Rilutek, and Tiglutik, according to Fortune Business Insight. The parenteral segment, meanwhile, is expected to grow at the fastest pace due to the approval of Biogen's QALSODY.
In terms of distribution channels, hospital pharmacies commanded the largest share, expected to reach 54.29% in 2026, owing to the presence of trained medical staff that reduces medication errors, according to Fortune Business Insight. The retail and online pharmacy segment is projected to grow at the fastest CAGR, fueled by expanding pharmacy networks and increased online availability of specialty drugs.
Regional Landscape
North America dominates the global market, accounting for a 54.37% share in 2025, with market value reaching USD 0.48 billion and projected to grow to USD 0.55 billion in 2026, according to Fortune Business Insight. The region's leadership stems from strong drug commercialization efforts and high disease awareness levels.
Europe contributed approximately USD 0.24 billion to the global market in 2025, representing a 26.82% share, and is anticipated to grow at a CAGR of 11.4% during the forecast period, according to Fortune Business Insight. This growth is linked to the commercialization of QALSODY and Radicava, along with anticipated approvals of pipeline drugs like PTC857 and AP-101.
The Asia Pacific region, valued at USD 0.09 billion in 2025, is expected to be the fastest-growing region, with China projected to post a CAGR of 14.30%, according to Fortune Business Insight. Japan's market is expected to reach USD 31.6 million by 2025, reflecting steady regional expansion supported by growing clinical trial activity from companies like PTC Therapeutics and Clene Nanomedicine.
Competitive Landscape
Leading players in the market include Biogen, Mitsubishi Tanabe Pharma, and Sanofi, all of which hold substantial market share due to their global commercialization strategies, according to Fortune Business Insight. Other notable companies such as Corcept Therapeutics, Annexon, Inc., PTC Therapeutics, Revalesio Corporation, and Clene Nanomedicine are focused on advancing clinical trials for next-generation therapeutics.
Conclusion
The ALS therapeutics market stands at a pivotal juncture, balancing the urgent need for effective treatments against challenges like high costs and side effects. With increasing government support, heightened disease awareness, and a robust pipeline of investigational drugs, the market is well-positioned for sustained growth through 2034. As pharmaceutical innovation continues to advance, patients living with this devastating disease may find greater hope in the years ahead.
Source:https://www.fortunebusinessinsights.com/amyotrophic-lateral-sclerosis-therapeutics-market-110139